Pharmaceuticals

Future Projections: Stem Cell Therapy Market to Reach $104.37 Million by 2029 at 7.0% CAGR

September 1, 2025 by Marketing Posting

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_

_x000D_

#What Is the Current and Projected Market Size of the Stem Cell Therapy Industry?#_x000D_

In recent times, there has been a significant growth in the market size of blood cancer drugs. The market which was valued at $74.69 billion in 2024, is predicted to grow to a value of $79.6 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 6.6%. Factors like advancements in research and development, an aging population, increased awareness and early diagnosis, along with regulatory approvals have contributed to the growth in the historical period._x000D_

_x000D_

The market size of blood cancer drugs is projected to experience significant growth in the coming years. It is forecasted to reach “$104.37 billion in 2029 with a compound annual growth rate (CAGR) of 7.0%. This expected growth during the forecast period can be linked to factors such as rising disease incidence, emerging markets, and supportive care. Key trends during the forecast period encompass investments in research and development, combination therapies, biomarker discovery, advancements in immunotherapy, and personalization of medicine._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=2587&type=smp_x000D_

_x000D_

#Which Factors Are Currently Driving The Growth Of The Stem Cell Therapy Market?_x000D_

The escalation in the incidence of chronic illnesses has aided the expansion of the stem cell therapy market. The prevalence of such diseases has been triggered by factors such as lengthy work schedules, minimal physical activity, and poor dietary and drinking habits, thereby enhancing the demand for stem cell therapy. A United Nations report anticipates that, by 2030, chronic diseases will account for 70% of total worldwide deaths. The global chronic disease burden is anticipated to hit around 60%. The growth in the prevalence of these chronic diseases is projected to fuel the growth of the stem cell therapy market._x000D_

_x000D_

The blood cancer drugs market covered in this report is segmented – _x000D_

_x000D_

1) By Blood Cancer Type: Leukemia, Lymphoma_x000D_

2) By Drugs: Rituxan Or Mabthera (Rituximab), Gleevec Or Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), Other Drugs _x000D_

3) By Treatment Approaches: Key Findings, Chemotherapeutic, MAbs/Targeted Therapies, Immunotherapeutic_x000D_

_x000D_

Subsegments:_x000D_

1) By Leukemia: Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Other Types of Leukemia _x000D_

2) By Lymphoma: Hodgkin Lymphoma, Non-Hodgkin Lymphoma (NHL), Burkitt Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Other Types of Lymphoma_x000D_

_x000D_

#Which Trends Are Redefining The Future Landscape Of The Stem Cell Therapy Industry?#_x000D_

A strategy employed by the key players in the blood cancer drugs market involves developing innovative drugs and obtaining FDA clearance to enhance their competitive position. FDA endorsement refers to the official permission given by the United States Food and Drug Administration (FDA) to legally sell a medicinal product in the United States. For example, in March 2024, Bristol Myers Squibb, an American pharmaceutical firm, obtained FDA approval for its first CAR T-cell therapy exclusively for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that was resistant or recurrent. The accelerated approval enables its use in patients who have undergone at least two prior therapies, including a Bruton tyrosine kinase inhibitor and a B-cell lymphoma 2 inhibitor. The TRANSCEND CLL 004 trial showed that Breyanzi had a complete response rate of 20% and a median duration of response of 35.3 months among those who responded._x000D_

_x000D_

#Who Are The Main Participants Shaping The Stem Cell Therapy Market Landscape?#_x000D_

Major companies operating in the blood cancer drugs market include Amgen Inc., AstraZeneca PLC, Bayer AG, Eli Lilly and Company Inc., Johnson & Johnson, Novartis AG, Pfizer Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Astellas Pharma Inc., Roche Holding AG, Merck & Co. Inc., Gilead Sciences Inc., Sanofi S.A., Eisai Co. Ltd., Jazz Pharmaceuticals plc, Kyowa Kirin Co. Ltd., Menarini Group, Millennium Pharmaceuticals Inc., Mundipharma International Limited, Mylan N.V., Ono Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Pharmacyclics LLC, Regeneron Pharmaceuticals Inc., Seattle Genetics Inc., Servier Laboratories, Shire plc, Spectrum Pharmaceuticals Inc., Taiho Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Tolero Pharmaceuticals Inc., UCB S.A., Vertex Pharmaceuticals Incorporated_x000D_

_x000D_

https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report_x000D_

_x000D_

#Which Region Currently Holds The Largest Share In The Stem Cell Therapy Market?#_x000D_

North America was the largest region in the blood cancer drugs market in 2024. Middle East is expected to be the fastest-growing region in the blood cancer drugs market during the forecast period. The regions covered in the blood cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa_x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=2587&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_